Literature DB >> 25182045

Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.

J R Stradling1, S E Craig1, M Kohler2, D Nicoll1, L Ayers3, A J Nunn4, D J Bratton4.   

Abstract

UNLABELLED: The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13). TRIAL REGISTRATION NUMBER: ISRCTN 34164388. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cytokine Biology; Sleep apnoea

Mesh：

Substances：

Year:  2014        PMID： 25182045     DOI： 10.1136/thoraxjnl-2014-205958

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  17 in total

1.  Obstructive sleep apnea and CPAP therapy alter distinct transcriptional programs in subcutaneous fat tissue.

Authors:  Sina A Gharib; Amanda L Hurley; Michael J Rosen; James C Spilsbury; Amy E Schell; Reena Mehra; Sanjay R Patel
Journal:  Sleep       Date:  2020-06-15       Impact factor: 5.849

2.  Developing Biomarker Arrays Predicting Sleep and Circadian-Coupled Risks to Health.

Authors:  Janet M Mullington; Sabra M Abbott; Judith E Carroll; Christopher J Davis; Derk-Jan Dijk; David F Dinges; Philip R Gehrman; Geoffrey S Ginsburg; David Gozal; Monika Haack; Diane C Lim; Madalina Macrea; Allan I Pack; David T Plante; Jennifer A Teske; Phyllis C Zee
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

Review 3.  Impact of Continuous Positive Airway Pressure on Cardiovascular Risk Factors in High-Risk Patients.

Authors:  Ying Y Zhao; Susan Redline
Journal:  Curr Atheroscler Rep       Date:  2015-11       Impact factor: 5.113

4.  Continuous positive airway pressure therapy in non-sleepy patients with obstructive sleep apnea: results of a meta-analysis.

Authors:  Dongmei Zhang; Jinmei Luo; Yixian Qiao; Yi Xiao
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 5.  Inflammation in sleep apnea: an update.

Authors:  Dileep Unnikrishnan; Jonathan Jun; Vsevolod Polotsky
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

6.  Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells.

Authors:  Katherine E Zychowski; Bethany Sanchez; Rodrigo P Pedrosa; Geraldo Lorenzi-Filho; Luciano F Drager; Vsevolod Y Polotsky; Matthew J Campen
Journal:  Atherosclerosis       Date:  2016-09-22       Impact factor: 5.162

7.  Effect of Continuous Positive Airway Pressure on Cardiovascular Biomarkers: The Sleep Apnea Stress Randomized Controlled Trial.

Authors:  Hugo L Paz Y Mar; Stanley L Hazen; Russell P Tracy; Kingman P Strohl; Dennis Auckley; James Bena; Lu Wang; Harneet K Walia; Sanjay R Patel; Reena Mehra
Journal:  Chest       Date:  2016-03-18       Impact factor: 9.410

8.  Roles of interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and treatment in obstructive sleep apnea: a meta-analysis.

Authors:  Anyuan Zhong; Xiaolu Xiong; Minhua Shi; Huajun Xu
Journal:  Sleep Breath       Date:  2015-11-13       Impact factor: 2.816

9.  Is Vimentin the Cause or Effect of Obstructive Sleep Apnea Development?

Authors:  Buğra Kerget; Dursun Erol Afşin; Ferhan Kerget; Seda Aşkın; Ömer Araz; Metin Akgün
Journal:  Lung       Date:  2020-02-22       Impact factor: 2.584

10.  Circulating Survivin Levels in Obstructive Sleep Apnoea.

Authors:  Laszlo Kunos; Peter Horvath; Adrian Kis; David Laszlo Tarnoki; Adam Domonkos Tarnoki; Zsofia Lazar; Andras Bikov
Journal:  Lung       Date:  2018-05-08       Impact factor: 2.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.